title: Activity of OZ78 analogues against Fasciola hepatica and Echinostoma caproni.
abstract: The rapid spread of triclabendazole resistance in veterinary medicine is an important motivation for the discovery and development of novel fasciocidal drugs. The aim of this study was to characterize the fasciocidal properties of 1,2,4,5-tetraoxane (MT04 and MT14) and 1,2,4-trioxane (ST16 and ST28) analogues of the fasciocidal drug candidate OZ78, a 1,2,4-trioxolane. Dose response relationships were determined against juvenile and adult Fasciola hepatica in rats and Echinostoma caproni in mice. The temporal effects of MT04, MT14, ST16, and ST28 compared to OZ78 on the viability of F. hepatica were tested in vitro. The heat flow of OZ78 and MT04 treated flukes was studied with isothermal microcalorimetry. Finally, surface changes to adult flukes were monitored by scanning electron microscopy (SEM) 18, 24, and 48 h post-treatment of rats with 50 mg/kg MT04. Administration of 50-100 mg/kg of the synthetic peroxides resulted in complete elimination of adult F. hepatica from rats. SEM pictures revealed sloughing and blebbing already 18 h post-treatment with MT04. MT04 (100mg/kg) cured infections with juvenile F. hepatica, whereas MT14, ST16, and ST28 showed only low to moderate worm burden reductions. At 300 mg/kg, MT14 was the only compound to completely eliminate worms from E. caproni infected mice. MT14 showed the highest activity against juvenile F. hepatica in vitro. MT04 was very active against adult F. hepatica in vitro, which was confirmed by heat flow measurements. In conclusion, we have identified MT04 as another lead compound with potential against F. hepatica, hence further preclinical studies are necessary to determine if MT04 can be considered a drug development candidate.
authors.affiliation: Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland.
authors.forename: Carla
authors.initials: C
authors.lastname: Kirchhofer
authors.forename: Mireille
authors.initials: M
authors.lastname: Vargas
authors.forename: Olivier
authors.initials: O
authors.lastname: Braissant
authors.forename: Yuxiang
authors.initials: Y
authors.lastname: Dong
authors.forename: Xiaofang
authors.initials: X
authors.lastname: Wang
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Vennerstrom
authors.forename: Jennifer
authors.initials: J
authors.lastname: Keiser
mesh_terms: D000218:Adamantane / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000737:chemistry; D004449:Echinostoma / Q000187:drug effects* / Q000648:ultrastructure; D004451:Echinostomiasis / Q000188:drug therapy*; D005210:Fasciola hepatica / Q000187:drug effects* / Q000648:ultrastructure; D005211:Fascioliasis / Q000188:drug therapy*; D005260:Female; D051379:Mice; D051381:Rats; D017208:Rats, Wistar; D016896:Treatment Outcome
chemical_list: D000871:Anthelmintics; C518172:OZ78 compound; D000218:Adamantane